<DOC>
	<DOCNO>NCT00464880</DOCNO>
	<brief_summary>This study assess reno-protective effect renin inhibition aliskiren alternative irbesartan type 2 diabetes patient incipient/overt diabetic nephropathy .</brief_summary>
	<brief_title>Effects Aliskiren , Irbesartan , Combination Hypertensive Patients With Type 2 Diabetes Diabetic Nephropathy</brief_title>
	<detailed_description>Antiproteinuric Effects Aliskiren ( Renin Inhibitor ) , Irbesartan ( Angiotensin Receptor Antagonist ) Combination Hypertensive Patients With Type 2 Diabetes Incipient/Overt Diabetic Nephropathy</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Male and/or female subject age 3080 year diagnosis type 2 diabetes ( World Health Organization criterion ) Body mass index ( BMI ) within range 20 32 . Incipient overt diabetic nephropathy ( urinary albumin excretion ≥ 100 ≤ 2000 mg/day ) . Glomerular filtration rate ( GFR ) ≥ 40 ml/min document last 4 month prior randomization To eligible randomization , patient must fulfill follow criterion : 1 . Patients ongoing hypertensive therapy must blood pressure ≥ 135/85 mmHg low 170/105 mmHg Visit 2 ( Day 1 ) AND patient must stable antihypertensive medication least 8 week prior Visit 2 ( runin period ) . 2 . Newly diagnose hypertensive patient must blood pressure ≥ 135/85 mmHg low 170/105 mmHg Visit 2 ( Day 1 ) . Patients must stable hypoglycemic medication least 8 week prior Visit 2 ( Day 1 ) . Patients must willing medically able discontinue angiotensinconverting enzyme inhibitor ( ACEI ) , angiotensin receptor blocker ( ARB ) , aldosterone receptor antagonist potassium spar diuretic medication duration study . Female patient must postmenopausal , bilateral oophorectomy , surgically sterilize hysterectomized least 6 month prior screen . Oral body temperature within range 35.037.5 °C Able provide write informed consent prior study participation . Able communicate well investigator comply requirement study . Severe hypertension , Grade 3 World Health Organization ( WHO ) classification ( mean sit diastolic blood pressure [ MSDBP ] ≥ 110 mmHg and/or mean sit systolic blood pressure [ MSSBP ] ≤ 180 mmHg ) Acetylsalicylic acid ( ASA ) treatment &gt; 1 g/day regular use nonsteroidal antiinflammatory drug ( NSAIDs ) Kidney disease cause diabetes hypertension Serum potassium &lt; 3.5 &gt; 5.1 mEq/L GFR &lt; 40 ml/min/1.73m2 measure Modification Diet Renal Disease ( MDRD ) formula Serum albumin &lt; 2.0 mg/dL History hypertensive encephalopathy cerebrovascular accident last 12 month prior Visit 1 Transient ischemic cerebral attack 6 month prior Visit 1 Current diagnosis heart failure ( New York Heart Association [ NYHA ] Class IIIV ) History myocardial infarction , unstable angina pectoris , coronary bypass surgery , percutaneous coronary intervention ( PCI ) 6 month prior Visit 1 Second third degree heart block without pacemaker Concurrent potentially life threaten arrhythmia symptomatic arrhythmia Clinically significant valvular heart disease Type 1 diabetes mellitus Uncontrolled type II diabetes mellitus ; hemoglobin subtype A1C ( HbA1C ) &gt; 11 % History malignancy include leukemia lymphoma ( basal cell skin carcinoma ) within past five year Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug include , limited , follow : History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection Currently active previously active inflammatory bowel disease 12 month prior Visit 1 Currently active gastritis , duodenal gastric ulcer , gastrointestinal/rectal bleed 3 month prior Visit 1 . Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase Evidence hepatic disease , history hepatic encephalopathy , history esophageal varix , history portacaval shunt Current treatment cholestyramine colestipol resins History immunocompromise , include positive test result . History positive hepatitis B surface antigen ( HBsAg ) hepatitis C test result . History drug alcohol abuse within 12 month prior dose . Persons directly involved execution protocol . Any condition , opinion investigator Novartis medical monitor , would jeopardize evaluation efficacy safety History noncompliance medical regimen unwillingness comply study protocol Known suspect contraindication study medication , include history allergy ACE inhibitor and/or thiazide diuretic sulfonamide derive drug Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study Use prescription drug overthecounter ( OTC ) medication prohibit protocol . Patients previously participate aliskiren study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Placebo-controlled study</keyword>
	<keyword>assess renoprotective effect renin inhibition</keyword>
	<keyword>Aliskiren alternative irbesartan</keyword>
	<keyword>Type 2 diabetes patient</keyword>
	<keyword>incipient/overt diabetic nephropathy</keyword>
</DOC>